Pre-market approval for Surpass Streamline flow diverter
The US Food and Drug Administration has granted pre-market approval (PMA) for the Surpass Streamline flow diverter to treat unruptured large and giant wide neck intracranial aneurysms, Stryker have announced in a press release. The device is the second flow diverting stent to gain FDA approval in the US. It is also approved and available in many markets around the world.
“Surpass Streamline is the first flow diverter indicated for large and giant posterior communicating artery aneurysms. These unruptured aneurysms are more challenging due to their location and surrounding anatomy. Having Surpass approved for this and other locations is an important advantage for physicians and patients,” said Philip Meyers, Professor of Radiology and Neurological Surgery at New York Presbyterian/Columbia University Medical Centre, New York, USA, and co-principal Investigator for the SCENT Investigational Device Exemption (IDE) trial which provided clinical outcomes to support Surpass PMA approval. “The stent is designed to reliably open and provide consistent mesh density across the neck of the aneurysm to aid in aneurysm occlusion while maintaining perforator artery patency.”
Ricardo Hanel, Director of the Baptist Neurological Institute at the Baptist Health System in Jacksonville, USA and co-principal Investigator for the SCENT IDE trial added, “SCENT is one of the largest, prospective, multicentre clinical trials on flow diversion that is generalisable to real world outcomes. This was the first flow diverter IDE study to show single stent efficacy while successfully meeting the primary and secondary endpoints. The ability to resheath, reposition and recapture the device without losing distal wire position is a significant advantage for Surpass.”